October 9, 2024: Angiolutions has further expanded its patent portfolio to 16 filed patents, protecting the device in various jurisdictions. This highlights Angiolutions’ commitment to safeguarding its innovative early-stage abdominal aortic aneurysm (AAA) treatment.

On Sep 24, Angiolutions second US patent was granted by the United States Patent and Trademark Office (USPTO).

On July 24, Angiolutions European (EP) patent was granted by the European Patent Office (EPO) less than 2 years after filing.

Dr. Uwe Raaz, co-founder and co-CEO, commented, “Securing this new IP is a significant milestone for Angiolutions. It underscores our dedication to innovation and our relentless effort developing the first implant to stop AAA at an early stage. We have been working hard to expand our IP protection and our work has been paying off.”

The expanded patent portfolio comprises 16 patents filed across five patent families and ringfences Angiolutions’ novel AAA treatment approach, its device implantation algorithm, as well as many critical features of the company’s device and corresponding delivery system.

Angiolutions’ efforts were further recognized with the 1st prize in the World IP Day Competition 2023 by the International Federation of Intellectual Property Attorneys.

Dr. Isabel Schellinger, co-founder and co-CEO, added, “We want to offer AAA patients a minimally invasive treatment that can stop their disease at an early stage. Strong IP is a cornerstone of our strategy. Our holistic IP portfolio goes beyond our device and ensures strong protection of our innovation from all angles.”

About Angiolutions

Angiolutions revolutionizes the treatment of life-threatening abdominal aortic aneurysms (AAAs) with a first-of-its-kind medical device that stops AAA growth at an early stage. AAA is a progressive dilation of the biggest blood vessel of our body affecting 1 in 20 people. By treating early-stage AAA, Angiolutions brings new hope to hundreds of thousands of patients that are currently without a treatment option.